A Long-Lasting HIV Vaccine for Initial Infection Sites
Official title: Durable HIV Vaccine Targeting Mucosal Epithelium
Funded at Texas Biomedical Research Institute · NIH-11135490 · Data updated 2026-11-12
This project is working to create a strong, long-lasting vaccine that protects against HIV right where the virus tries to enter the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Biomedical Research Institute NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $963,873 |
| NIH project number | 5R01AI172539-04 |
| Project ID | NIH-11135490 on NIH RePORTER |
Who could benefit from this research
✓Could help
Future participants in related clinical trials would likely be healthy individuals at risk of HIV exposure.
✕Less likely to help
Patients already living with HIV would not directly benefit from this preventative vaccine.
What this research studies
This research aims to develop an HIV vaccine that provides two layers of protection: an initial barrier at the body's entry points, like mucosal tissues, and a second set of defenses throughout the body if the first barrier is breached. The goal is to keep the immune system constantly alert to HIV and target the immune response specifically to the initial infection sites. This innovative strategy uses epithelial stem cells to continuously present viral antigens, aiming to build solid, long-term protection against the virus.
Why it matters
Potential benefit: If successful, this vaccine could offer a new way to prevent HIV infection by providing robust, long-term protection at the body's primary entry points.
How similar studies have gone: While previous HIV vaccine efforts have provided valuable insights, this project explores an original strategy for delivering a vaccine to mucosal sites.
Where this research is happening
-
Texas Biomedical Research Institute
San Antonio, United States Active
Researchers
- Principal investigator: Gauduin, Marie-Claire Elisabeth — Texas Biomedical Research Institute
- Study coordinator: Gauduin, Marie-Claire Elisabeth
Related research
Other NIH-funded projects on the same topics.
-
Targeting human HIV latency with super-enhancer RNA targets
A short, patient-friendly plan to explore how special RNA molecules in immune cells control HIV hiding in the body and how we might disrupt that to help control the virus.
-
Pathways to trigger protective MAIT cell responses against bacterial infections
A study to figure out which bacterial metabolite antigens activate MAIT cells through MR1 to defend against TB and tularemia.
-
IL-21 therapy to boost lung immunity in HIV/TB co-infection
A study tests an IL-21-based therapy added to HIV treatment to help the lungs control TB and reduce HIV persistence in people (or animal models that simulate them).
-
Focused ultrasound to open the blood-brain barrier and reduce HIV reservoirs in the brain
A new approach uses gentle ultrasound to temporarily open the brain’s protective barrier so HIV medicines can reach the brain and shrink hidden virus reservoirs in people living with HIV.
-
Macrophage biology and metabolism in TB infection
Researchers are studying human lung macrophages to understand how they regulate immune responses and support or limit tuberculosis infection, with the goal of improving treatments that help the body fight TB.
-
Understanding how genetics and immunity shape chikungunya brain disease
A research project uses genetically diverse mice to learn why chikungunya virus causes brain inflammation in some people and how immune responses contribute to this disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.